ClinicalTrials.gg
TerminatedNCT03493464Updated Sep 19, 2024Results posted

BR55 in Characterization of Ovarian Lesions

A Phase 2 interventional study of BR55 in Ovarian Cancer, sponsored by Bracco Diagnostics, Inc. Terminated at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-09-19.

Sponsored by Bracco Diagnostics, Inc (part of Bracco) · Phase 2, Interventional, and Diagnostic

Why this study was terminated
Sponsor decision; expiration of available study agent due to long recruitment timeline.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
14
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,780 studies in Ovarian Neoplasms with a site in United States — 277 open to participants now, 453 under way, 46 of them phase 3. Ovarian Neoplasms · United States.

Enrollment
1,245th of 1,499
14 · median 47
Started
2018
with 75 others
Phase 2
485 of 1,780
53 open now
Registered
1,111th of 1,780
by date

Among the 1,780 studies in Ovarian Neoplasms with a site in United States, this one is the 1,245th largest by enrollment of the 1,499 interventional ones that give a count, is one of 76 that started in 2018, is one of 485 in phase 2, and was the 1,111th registered.

Ovarian Neoplasms

3,389 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

277 of the 1,780 studies in Ovarian Neoplasms with a site in United States are open now. Recruiting first, the newest first:

272 more — sign in →

All 277 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 601 Ovarian Neoplasms studies recruiting now, 438 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,780 studies in Ovarian Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This is an exploratory phase II, single center, open label, prospective study of BR55 CEUS for characterization of ovarian lesions in subjects with suspected ovarian cancer.

Read the detailed description

A total of sixty (60) subjects scheduled to undergo salpingo-oophorectomy within 30 days of BR55 CEUS examination will be enrolled to obtain approximately 30 subjects with benign ovarian lesions and 30 with malignant ovarian lesions based on the truth standard (TS).

The first 10 subjects will receive BR55 at a dose of 0.03 mL/kg. Assuming these first 10 subjects will show technically adequate images, subsequent subjects enrolled in the study will continue to receive 0.03 mL/kg dose of BR55; otherwise, subjects will be switched to a 0.05 mL/kg dose of BR55.

The final cancer diagnosis will be obtained for all subjects by histopathology.

03

Conditions studied

  • Ovarian Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: Enroll a subject if he/she meets the following inclusion criteria:

  • Is at least 18 years of age;
  • Has an ovarian lesion that is visible and assessable with trans-vaginal ultrasound;
  • Is scheduled to undergo salpingo-oophorectomy for suspected ovarian cancer not earlier than 24 hours and not later than 30 days following BR55 administration;
  • Provides written and is willing to comply with protocol requirements.

Exclusion Criteria: Exclude a subject if the subject does not fulfill the inclusion criteria, or if any of the following conditions are observed:

  • Is a pregnant or lactating female. Exclude the possibility of pregnancy:

    • by testing on site at the institution (serum βHCG) within 24 hours prior to the start of product administration,
    • by surgical history (e.g., tubal ligation or hysterectomy),
    • by status with a minimum 1 year without menses;
  • Has undergone prior systemic therapy for ovarian cancer;
  • Has history of concurrent ;
  • Has history of any clinically unstable cardiac condition including class III/IV congestive heart failure;
  • Has had any severe cardiac rhythm disorders within 7 days prior to enrolment;
  • Has severe pulmonary hypertension (pulmonary artery pressure >90mmHg) or uncontrolled systemic hypertension and/or respiratory distress syndrome;
  • Has open and/or non-healing wounds in the chest, abdomen and pelvis;
  • Has other systemic vascular abnormalities associated with neovascularization, such as macular degeneration, that in the opinion of the investigator could significantly affect the ability to evaluate the effects of BR55;
  • Is participating in a clinical trial or has participated in another trial with an investigational compound within the past 30 days prior to enrolment;
  • Has previously been enrolled in and completed this study;
  • Has any known allergy to one or more of the ingredients of the Investigational Product or to any other contrast media;
  • Is determined by the Investigator that the subject is clinically unsuitable for the study;
  • Has had major surgery, including laparoscopic surgery, within 3 months prior to enrolment;
  • Has history of surgery to the ovaries or pelvic inflammatory disease.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
14 participants (actual)

Study arms

  • Experimental
    Treatment

    Subjects will receive a single dose of BR55 at 0.03 mL/kg or 0.05 mL/kg.

    Drug: BR55

Interventions

  • DrugBR55

    A novel targeted ultrasound contrast agent

06

What researchers measure

Primary outcomes

  1. Visual Assessment of BR55 Enhancement

    BR55-enhanced images will be visually assessed using a 3-point scale (no enhancement=no focal targeted, stationary imaging signal was detectable; weak enhancement=weak focal targeted imaging signal was detectable and considered possibly stationary; strong enhancement=well-defined and strong focal targeted imaging signal was detectable and considered as definitely stationary).

    Time frame: 30 minutes post-dose on Day 1

  2. Adverse Events

    Number of participants who received the contrast agent and experienced an adverse event.

    Time frame: 2 days (day of and 24 hours after BR55 administration)

07

Results

Posted Sep 19, 2024

Participant flow

A total of 60 subjects scheduled to undergo salpingo-oophorectomy within 30 days of BR55 contrast-enhanced ultrasound (CEUS) examination were to be enrolled to obtain approx. 30 subjects with benign ovarian lesions and 30 with malignant ovarian lesions based on the Truth Standard (TS; histopathology). This study was terminated early due to expiration of available BR55, therefore, only 14 of the 60 anticipated participants in the study were enrolled.

Participant flow — Overall Study
MilestoneTreatment
Started14
Completed13
Not completed1
Withdrew: Surgery not performed1

Outcome measures

PrimaryVisual Assessment of BR55 Enhancement

BR55-enhanced images will be visually assessed using a 3-point scale (no enhancement=no focal targeted, stationary imaging signal was detectable; weak enhancement=weak focal targeted imaging signal was detectable and considered possibly stationary; strong enhancement=well-defined and strong focal targeted imaging signal was detectable and considered as definitely stationary).

Time frame:
30 minutes post-dose on Day 1
Reported as:
Count of participants · Participants
Visual Assessment of BR55 Enhancement
ParticipantsTreatment
No enhancement5
Weak enhancement6
Strong enhancement3
PrimaryAdverse Events

Number of participants who received the contrast agent and experienced an adverse event.

Time frame:
2 days (day of and 24 hours after BR55 administration)
Reported as:
Count of participants · Participants
Adverse Events
ParticipantsTreatment
Adverse Events3

Adverse events

Collected over Safety monitoring began at the time of signing Informed Consent and continued for 24 hours after BR55 administration, up to 3 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment0/14 (0%)0/14 (0%)3/14 (21.4%)
Most frequent other events
Most frequent other events
EventTreatment
HeadacheNervous system disorders3/14
ItchinessGeneral disorders1/14

Baseline characteristics

All participants enrolled and dosed in the study who provided demographic information.

Age, Categorical
Age, Categorical(Participants)Treatment
<=18 years0
Between 18 and 65 years10
>=65 years4
Age, Continuous
Age, Continuous(years)Treatment
Mean55.4 (28 to 76)
Sex: Female, Male
Sex: Female, Male(Participants)Treatment
Female14
Male0
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Treatment
Hispanic or Latino2
Not Hispanic or Latino12
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Treatment
American Indian or Alaska Native0
Asian4
Native Hawaiian or Other Pacific Islander0
Black or African American0
White10
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Treatment
United States14
Exposure to Investigational Product
Exposure to Investigational Product(Actual Volume Administered (mL))Treatment
Mean2.16 ± 0.246
08

Study locations

1 site
  • Stanford University Medical Center
    Palo Alto, California 94304, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2018 to primary completion in Apr 2021, 28 months.

Results were first posted in Sep 2024, 3 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 4, 2018
First posted
Apr 10, 2018
StartActual
Dec 13, 2018
Primary completionActual
Apr 15, 2021
CompletionActual
Jul 31, 2021
Results first posted
Sep 19, 2024
Last update
Sep 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03493464
Responsible party
Sponsor
First posted
Apr 10, 2018
Start date
Dec 13, 2018
Primary completion
Apr 15, 2021
Completion
Jul 31, 2021
Results posted
Sep 19, 2024
Last update
Sep 19, 2024

Study contacts

Maria Luigia Storto, MD
study director · Bracco Diagnostics, Inc

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BR55

Start the discussion